Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Libtayo sales are being driven by growth in demand for non-melanoma skin indications, coupled with increased utilization in both monotherapy and chemotherapy combination settings in lung cancer.

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

Patients with pathologically confirmed solid tumors were treated with ICIs consisting of anti-PD-1/PD-L1 blockade (nivolumab [Opdivo], pembrolizumab [Keytruda], atezolizumab [Tecentriq], cemiplimab ...

Dancing it out can be a great way to recover from chemo. That's according to new research from The Ohio State University Comprehensive Cancer Center, which found that dancing the tango can boost ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion, while the ...

An oral chemo drug is safe and effective for sickle cell disease in children Hydroxyurea helps red blood cells retain a healthy, round shape The drug significantly reduced ER visits and hospital ...

HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with ...